TI
BTAI icon

Trexquant Investment’s BioXcel Therapeutics BTAI Stock Holding History

Trexquant Investment’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-413
Closed -$351K – 1209
2020
Q2 		$351K Buy
+413
New +$269K 0.02% 805

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Trexquant Investment's BTAI Position: Q3 2020 in Review

Trexquant Investment sold out of BioXcel Therapeutics (BTAI) in Q3 2020, closing a stake of 413 shares — an estimated $351K sold.

Trexquant Investment first reported a position in BTAI in Q2 2020 and held it in 1 quarter. The position peaked at $351K in Q2 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q3 2020.

  • Trexquant Investment reported no remaining BioXcel Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Trexquant Investment sold 413 BioXcel Therapeutics shares in Q3 2020, an estimated $351K.
  • Trexquant Investment first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 1 quarter.
  • Trexquant Investment's BioXcel Therapeutics position peaked at $351K in Q2 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2020.

Based on Trexquant Investment's 13F filing for Q3 2020, filed 6 Nov 2020.